CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $3.83M, lower than 95% of all stocks globally
- PositionGross margin is 5.2%, lower than 95% of its Biotechnology peers (median 67.2%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
390.26BKRW281.69M · vs all stocks (USD)
Revenue (TTM)
5.31BKRW3.83M · vs all stocks (USD)
Beta
0.8060xvs all stocks
52-Week Change
27.01%vs all stocks
Market Capitalization
390.26BKRW281.69M · vs all stocks (USD)
Enterprise Value
361.47BKRW260.91M · vs all stocks (USD)
Price to Sales (TTM)
73.53xvs Biotechnology peers
Price to Book (MRQ)
7.23xvs Biotechnology peers
Enterprise to Revenue
68.10xvs Biotechnology peers
Enterprise to EBITDA
-20.96xvs Biotechnology peers
Gross Margin
5.16%vs Biotechnology peers
Operating Margin
-371.39%vs Biotechnology peers
Return on Assets (TTM)
-21.37%vs Biotechnology peers
Return on Equity (TTM)
-40.78%vs Biotechnology peers
Revenue (TTM)
5.31BKRW3.83M · vs all stocks (USD)
Revenue per Share (TTM)
271.75KRWUpdated Sep 20, 2026Quarterly Revenue Growth
51.40%vs Biotechnology peers
Gross Profit (TTM)
645.83MKRW466.16K · vs all stocks (USD)
EBITDA (TTM)
-17.25BKRW-12.45M · vs all stocks (USD)
Net Income (TTM)
-17.73BKRW-12.80M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
51.44%vs Biotechnology peers
Operating Cash Flow (TTM)
-13.64BKRW-9.85M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.92BKRW-6.44M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
4.71BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
3.57BKRWFY2025 · Dec 31, 2025Gross Profit
1.14BKRWFY2025 · Dec 31, 2025Operating Income
-17.64BKRW-12.73M · vs all stocks (USD)
Pre-tax Income
-17.91BKRWFY2025 · Dec 31, 2025Income Tax Expense
-2.37MKRWFY2025 · Dec 31, 2025Net Income
-17.91BKRWFY2025 · Dec 31, 2025EBIT
-17.47BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-16.09BKRWFY2025 · Dec 31, 2025Research & Development
14.43BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
1.42BKRWFY2025 · Dec 31, 2025Other Operating Expenses
316.84MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
457.67MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
438.68MKRWFY2025 · Dec 31, 2025EPS (Basic)
-976.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-976.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
18.35MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
18.35MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-17.91BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-17.13BKRWFY2025 · Dec 31, 2025Free Cash Flow
-17.73BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
39.01BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-17.91BKRWFY2025 · Dec 31, 2025Stock-based Compensation
808.55MKRWFY2025 · Dec 31, 2025Other Non-cash Items
3.14MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-49.76MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
13.02MKRWFY2025 · Dec 31, 2025Capital Expenditures
-593.70MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-23.95MKRWFY2025 · Dec 31, 2025Purchase of Investments
-6.00BKRWFY2025 · Dec 31, 2025Sale of Investments
3.00BKRWFY2025 · Dec 31, 2025Other Investing Activity
-155.73MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.75BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
25.16BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-10.10BKRWFY2025 · Dec 31, 2025Other Financing Charges
-95.87MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
37.91BKRWFY2025 · Dec 31, 2025Shares Outstanding
19.93MSharesUpdated Sep 20, 2026Float Shares
15.94MSharesUpdated Sep 20, 2026% Held by Insiders
19.92%vs all stocks
% Held by Institutions
3.13%vs all stocks
Total Cash (MRQ)
36.38BKRW26.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.82KKRWUpdated Sep 20, 2026Total Debt (MRQ)
7.44BKRW5.37M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1402xvs Biotechnology peers
Current Ratio (MRQ)
3.89xvs Biotechnology peers
Book Value per Share (MRQ)
2.71KKRWUpdated Sep 20, 2026Total Assets
70.75BKRW51.06M · vs all stocks (USD)
Total Current Assets
46.04BKRWFY2025 · Dec 31, 2025Total Liabilities
10.31BKRWFY2025 · Dec 31, 2025Total Non-current Assets
24.71BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
955.19MKRWFY2025 · Dec 31, 2025Total Current Liabilities
9.35BKRWFY2025 · Dec 31, 2025Cash
39.01BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
39.01BKRWFY2025 · Dec 31, 2025Other Short-term Investments
6.00BKRWFY2025 · Dec 31, 2025Accounts Receivable
280.26MKRWFY2025 · Dec 31, 2025Inventory
186.59MKRWFY2025 · Dec 31, 2025Accounts Payable
6.96MKRWFY2025 · Dec 31, 2025Short-term Debt
7.04BKRWFY2025 · Dec 31, 2025Other Current Liabilities
-570.00KRWFY2025 · Dec 31, 2025Long-term Debt
46.26MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
60.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
9.86BKRWFY2025 · Dec 31, 2025Retained Earnings
-90.79BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
60.44BKRW43.62M · vs all stocks (USD)
52-Week Low
13.59KKRWUpdated Sep 20, 202652-Week High
95.80KKRWUpdated Sep 20, 202652-Week Change
27.01%vs all stocks
Beta
0.8060xvs all stocks
50-Day MA
23.92KKRWUpdated Sep 20, 2026200-Day MA
43.25KKRWUpdated Sep 20, 2026Avg 10-Day Volume
93.17KSharesUpdated Sep 20, 2026Avg 30-Day Volume
187.95KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
-976.00KRWUpdated Sep 20, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Working Capital Pattern
What customers owe has grown three years running, while it clears stock quickly and pays suppliers quickly.
Reads
Three Turnover Ratios Elevated
Collects fast, clears inventory fast, and pays suppliers fast too.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 5.2%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 0.05Industry median: 0.67Industry P5: 0.14Peers compared: 260
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $3.83M, lower than 95% of all stocks globallySignificant
Revenue (USD): 3,831,095.065Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Sichuan Gangtong Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Elite Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tiansheng Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guangdong Jiaying Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Wiwynn Corporation
4 interpretationsWorking Capital PatternDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedThree Turnover Ratios Elevated
FlyExclusive Inc.
4 interpretationsWorking Capital PatternDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedThree Turnover Ratios Elevated
LDR Turizm A.S.
4 interpretationsWorking Capital PatternDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedThree Turnover Ratios Elevated